Back to companies

Swedish Orphan Biovitrum AB: Overview

Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS) and Hemophilia A. Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

Headquarters Sweden

Address Tomtebodavagen 23a, Solna, 17165


Telephone 46 8 6972000

No of Employees 1,554

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange SOBI (STO)

Revenue (2020) $1.8B 1.8% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX -17.4% (2020 vs 2019)

Market Cap* $6.9B

Net Profit Margin (2020) XXX -18.9% (2020 vs 2019)

* As of and is in US$

Access premium data and analytics for Swedish Orphan Biovitrum AB

140+

Clinical Trials

Determine Swedish Orphan Biovitrum AB go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Catalyst Calendar

Proactively evaluate Swedish Orphan Biovitrum AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

60+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Swedish Orphan Biovitrum AB’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of Swedish Orphan Biovitrum AB’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Swedish Orphan Biovitrum AB and assess market opportunity for new entrants with patient population 8-year forecasts.

17+

Marketed Drugs

Understand Swedish Orphan Biovitrum AB’s commercialized product portfolio to stay one step ahead of the market.

16+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Investigators

Review investigator profiles and find information on trial contacts across Swedish Orphan Biovitrum AB, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

130+

Install Base

Install Base provides the user with a holistic as well as granular level view of the product deployments of leading vendors across geographies and sectors. Using the tool users can also get an understanding of various vendors’ products or solutions deployed by a prospect.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Hematology:
Elocta
Alprolix
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In July, the company and ADC Therapeutics entered into a licensing agreement to develop and market Zynlonta for hematologic and solid tumour indications in Europe.
2022 New Products/Services In June, Sobi North America announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis (HLH).
2021 Others In December, the company announced US$8 billion public cash offer was withdraw by Advent International and GIC.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Swedish Orphan Biovitrum AB BioGaia AB New Nordic Healthbrands AB Hansa Biopharma AB Vivesto AB
Headquarters Sweden Sweden Sweden Sweden Sweden
City Solna Stockholm Malmo Lund Solna
No. of Employees 1,554 195 37 145 19
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Hakan Bjorklund Ph.D. Chairman Executive Board 2016 66
Guido Oelkers Chief Executive Officer Senior Management 2017 57
Henrik Stenqvist Chief Financial Officer Senior Management 2018 55
Norbert Oppitz Head - International Senior Management 2017 55
Torbjorn Hallberg Head - Legal Affairs and Human Resources; General Counsel Senior Management 2018 53
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer